An outcomes-based, innovative reimbursement mechanism for curative medicines
Cell & Gene Therapy Insights 2019; 5(8), 859-865.
Published: 3 September 2019
Omar Ali qualified as a hospital pharmacist and has extensive experience as an NHS formulary pharmacist reviewing cost effectiveness of medicines for access and reimbursement at regional and national level. He was a former adviser to NICE on the ERG for adoptiona and impact of new medicines. He is currently working towards a PhD in value-based agreements and innovative contracting for new medicines, last year authoring on a paper providing a methodological framework for CAR-T reimbursment based upon remission (pay for performance model) over time.